Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q Stock Report

Market Cap: US$4.0m

Eiger BioPharmaceuticals Management

Management criteria checks 2/4

Eiger BioPharmaceuticals' CEO is David Apelian, appointed in Dec 2022, has a tenure of 1.33 years. total yearly compensation is $204.39K, comprised of 15.1% salary and 84.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $979.73. The average tenure of the management team and the board of directors is 1.3 years and 5.8 years respectively.

Key information

David Apelian

Chief executive officer

US$204.4k

Total compensation

CEO salary percentage15.1%
CEO tenure1.3yrs
CEO ownership0.02%
Management average tenure1.3yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20
Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Oct 05

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Sep 06

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Jul 26

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Jul 20

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Apr 06

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Mar 15
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst

Dec 26

CEO Compensation Analysis

How has David Apelian's remuneration changed compared to Eiger BioPharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$75m

Sep 30 2023n/an/a

-US$87m

Jun 30 2023n/an/a

-US$96m

Mar 31 2023n/an/a

-US$97m

Dec 31 2022US$204kUS$31k

-US$97m

Sep 30 2022n/an/a

-US$93m

Jun 30 2022n/an/a

-US$89m

Mar 31 2022n/an/a

-US$86m

Dec 31 2021US$149kn/a

-US$34m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$102kn/a

-US$65m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$2mUS$272k

-US$70m

Sep 30 2019n/an/a

-US$70m

Jun 30 2019n/an/a

-US$68m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$3mUS$514k

-US$52m

Sep 30 2018n/an/a

-US$47m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$40m

Dec 31 2017US$194kn/a

-US$42m

Compensation vs Market: David's total compensation ($USD204.39K) is below average for companies of similar size in the US market ($USD670.12K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Apelian (58 yo)

1.3yrs

Tenure

US$204,386

Compensation

Dr. David Apelian, M.D., Ph D., MBA, served as Chief Executive Officer and Director of Bluesphere Bio, Inc. since July 2019. Dr. Apelian served as Chief Operating Officer and Executive Medical Officer at E...

Leadership Team

NamePositionTenureCompensationOwnership
David Apelian
CEO & Director1.3yrsUS$204.39k0.025%
$ 979.7
William Kaichoff
CFO and Principal Financial & Accounting Officerless than a yearno datano data
Christopher Kurtz
Chief Technical Officer2yrsno datano data
James Vollins
General Counsel1.3yrsno datano data

1.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: EIGR.Q's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
David Apelian
CEO & Director6.8yrsUS$204.39k0.025%
$ 979.7
Thomas Dietz
Independent Chairman8.1yrsUS$274.58k0.16%
$ 6.3k
Amit Sachdev
Independent Director5yrsUS$135.09k0.036%
$ 1.4k
Lisa Kelly-Croswell
Independent Director1.8yrsUS$181.07k0%
$ 0
Stanley Rockson
Scientific Advisorno datano datano data
Evan Loh
Independent Director6.6yrsUS$137.09k0.032%
$ 1.2k
Tracey McLaughlin
Scientific Advisorno datano datano data
Kim Sablich
Director3yrsUS$124.59k0.014%
$ 534.1

5.8yrs

Average Tenure

57yo

Average Age

Experienced Board: EIGR.Q's board of directors are considered experienced (5.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.